학술논문
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
Document Type
Article
Author
Fürstenau, Moritz; Thus, Yvonne J; Robrecht, Sandra; Mellink, Clemens HM; van der Kevie-Kersemaekers, Anne-Marie; Dubois, Julie; von Tresckow, Julia; Patz, Michaela; Gregor, Michael; Thornton, Patrick; Staber, Philipp B.; Tadmor, Tamar; Levin, Mark-David; da Cunha-Bang, Caspar; Schneider, Christof; Poulsen, Christian Bjoern; Illmer, Thomas; Schöttker, Björn; Janssens, Ann; Christiansen, Ilse; Nösslinger, Thomas; Baumann, Michael; Hebart, Holger; Gaska, Tobias; Regelink, Josien C; Dompeling, Ellen C; Lindström, Vesa; Juliusson, Gunnar; Widmer, Anouk; Goede, Jeroen; Goldschmidt, Neta; Simon, Florian; De Silva, Nisha; Fink, Anna-Maria; Fischer, Kirsten; Wendtner, Clemens-Martin; Ritgen, Matthias; Brüggemann, Monika; Tausch, Eugen; Spaargaren, Marcel; Eldering, Eric; Stilgenbauer, Stephan; Niemann, Carsten U; Hallek, Michael; Eichhorst, Barbara; Kreuzer, Karl-Anton; Kater, Arnon P
Source
Blood; 20230101, Issue: Preprints
Subject
Language
ISSN
00064971; 15280020
Abstract
•Highly complex karyotypes (≥5 chromosomal aberrations) and translocations are independent prognostic factors for inferior progression-free survival in patients with TP53-intact CLL treated with venetoclax-based combinations•While chemoimmunotherapy was associated with an increase in chromosomal aberrations at clinical progression of CLL, karyotype complexity did not increase after venetoclax-based treatments